pharma news today obesity drugs glp-1 october 2025 Agonists Weight Loss Market Report, 2025-2030 GLP-1 Overdoses Are Rising as

Suitable for a range of dietary lifestyles

This patch helps suppress appetite, supporting portion control and reducing the temptation to overeat

Oral semaglutide at doses of up to 14 mg daily is approved for T2D and doses as high as 50 mg daily have been evaluated for weight loss, with 25 mg daily filed for approval for the treatment of obesity.

Shima Hadidchi MD Offered Semaglutide GLP-1 Injections to Help Obese Adults to Achieve Substantial Weight Loss & Improved Overall Health.

The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease